先天性脂肪代谢障碍蛋白2抗体Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Defects in BSCL2 are the cause of congenital generalized lipodystrophy type 2 (CGL2) . Congenital generalized lipodystrophy is an autosomal recessive disorder characterized by a near absence of adipose tissue, extreme insulin resistance, hypertriglyceridemia, 先天性脂肪代谢障碍蛋白2抗体hepatic steatosis and early onset of diabetes.
Defects in BSCL2 are the cause of spastic paraplegia type 17 (SPG17) ; also known as Silver spastic paraplegia syndrome. Spastic paraplegia is a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. SPG17 is characterized by prominent amyotrophy of the hand muscles, the presence of mild to severe pyramidal tract signs,先天性脂肪代谢障碍蛋白2抗体 and spastic paraplegia.
SPG17 is a motor neuron disease overlapping with distal spinal muscular atrophy type 5. Defects in BSCL2 are a cause of distal hereditary motor neuropathy type 5 (HMN5); also known aS distal hereditary motor neuropathy type V (DSMAV). HMN5 is an autosomal dominant disorder characterized by degeneration of motor nerve fibers, predominantly in limb distal regions.
先天性脂肪代谢障碍蛋白2抗体Also known as:
Bernardinelli Seip congenital lipodystrophy 2; Bernardinelli Seip congenital lipodystrophy type 2 protein; Bernardinelli-Seip congenital lipodystrophy type 2 protein; BSCL 2; BSCL2; BSCL2_HUMAN; GNG3LG; HMN 5; HMN5; MGC4694; Seipin; Spastic paraplegia 17 (autosomal dominant); Spastic paraplegia 17 (Silver syndrome); Spastic paraplegia 17; Spastic paraplegia with amyotrophy of hands and feet (Silver syndrome); Spastic paraplegia with amyotrophy of hands and feet; SPG 17; SPG17.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Cow, Horse, Rabbit, .
●
Immunogen: KLH conjugated synthetic peptide derived from human BSCL2/SPG17.
●
先天性脂肪代谢障碍蛋白2抗体Predicted Molecular Weight: 44kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
kl129Fi01组织金属蛋白酶抑制因子3(TIMP3)多克隆抗体Polyclonal Antibody to Tissue Inhibitors Of Metalloproteinase 3 (TIMP3)
kl129Ga01组织金属蛋白酶抑制因子3(TIMP3)多克隆抗体Polyclonal Antibody to Tissue Inhibitors Of Metalloproteinase 3 (TIMP3)
kl129Hu01组织金属蛋白酶抑制因子3(TIMP3)多克隆抗体Polyclonal Antibody to Tissue Inhibitors Of Metalloproteinase 3 (TIMP3)
kl129Mu01组织金属蛋白酶抑制因子3(TIMP3)多克隆抗体Polyclonal Antibody to Tissue Inhibitors Of Metalloproteinase 3 (TIMP3)
kl129Po01组织金属蛋白酶抑制因子3(TIMP3)多克隆抗体Polyclonal Antibody to Tissue Inhibitors Of Metalloproteinase 3 (TIMP3)
kl129Ra01组织金属蛋白酶抑制因子3(TIMP3)多克隆抗体Polyclonal Antibody to Tissue Inhibitors Of Metalloproteinase 3 (TIMP3)
kl129Rb51组织金属蛋白酶抑制因子3(TIMP3)多克隆抗体Polyclonal Antibody to Tissue Inhibitors Of Metalloproteinase 3 (TIMP3)
kl129Si01组织金属蛋白酶抑制因子3(TIMP3)多克隆抗体Polyclonal Antibody to Tissue Inhibitors Of Metalloproteinase 3 (TIMP3)
kl130Bo01组织金属蛋白酶抑制因子4(TIMP4)多克隆抗体Polyclonal Antibody to Tissue Inhibitors Of Metalloproteinase 4 (TIMP4)
kl130Hu01组织金属蛋白酶抑制因子4(TIMP4)多克隆抗体Polyclonal Antibody to Tissue Inhibitors Of Metalloproteinase 4 (TIMP4)
kl130Mu01组织金属蛋白酶抑制因子4(TIMP4)多克隆抗体Polyclonal Antibody to Tissue Inhibitors Of Metalloproteinase 4 (TIMP4)
kl130Po01组织金属蛋白酶抑制因子4(TIMP4)多克隆抗体Polyclonal Antibody to Tissue Inhibitors Of Metalloproteinase 4 (TIMP4)
kl130Ra01组织金属蛋白酶抑制因子4(TIMP4)多克隆抗体Polyclonal Antibody to Tissue Inhibitors Of Metalloproteinase 4 (TIMP4)
kl130Rb51组织金属蛋白酶抑制因子4(TIMP4)多克隆抗体Polyclonal Antibody to Tissue Inhibitors Of Metalloproteinase 4 (TIMP4)
kl131Bo01转化生长因子β诱导蛋白(TGFβI)多克隆抗体Polyclonal Antibody to Transforming Growth Factor Beta Induced Protein (TGFbI)
kl131Fi01转化生长因子β诱导蛋白(TGFβI)多克隆抗体Polyclonal Antibody to Transforming Growth Factor Beta Induced Protein (TGFbI)
kl131Hu01转化生长因子β诱导蛋白(TGFβI)多克隆抗体Polyclonal Antibody to Transforming Growth Factor Beta Induced Protein (TGFbI)
kl131Mu01转化生长因子β诱导蛋白(TGFβI)多克隆抗体Polyclonal Antibody to Transforming Growth Factor Beta Induced Protein (TGFbI)
kl131Po01转化生长因子β诱导蛋白(TGFβI)多克隆抗体Polyclonal Antibody to Transforming Growth Factor Beta Induced Protein (TGFbI)
kl131Rb51转化生长因子β诱导蛋白(TGFβI)多克隆抗体Polyclonal Antibody to Transforming Growth Factor Beta Induced Protein (TGFbI)
kl132Hu01脂联素受体2(ADIPOR2)多克隆抗体Polyclonal Antibody to Adiponectin Receptor 2 (ADIPOR2)
更多
企业名称
上海康朗生物科技有限公司
企业信息已认证
企业类型
信用代码
310112001510759
成立日期
2015-05-29
注册资本
100
经营范围
从事生物科技技术领域内技术开发、技术咨询、技术服务、技术转让,实验分析仪器、化工产品及原料(除危险化学品、监控化学品、烟花爆竹、民用爆竹物品、易制毒化学品)、仪器仪表、环保设备、酒店用品、皮革制品、床上用品、电子产品的销售。【依法须经批准的项目,经相关部门批准后方可开展经营活动】
上海康朗生物科技有限公司
公司地址
上海市闵行区闵北路88弄1-30号第22栋BV145室
客服电话